1. Preprint › Research
2. Published

   The costs and cost-effectiveness of different service models of palliatice care, focusing on end of life care: A rapid review

   Spencer, L., Anthony, B., Davies, J., Pisavadia, K., Gillen, E., Noyes, J., Fitzsimmons, D., Lewis, R., Cooper, A., Hughes, D., Edwards, R. T. & Edwards, A., 7 Mar 2024, MedRxiv, 118 p.

   Research output: Working paper › Preprint

3. Published

   What interventions or best practice are there to support people with Long COVID, or similar post-viral conditions or conditions characterised by fatigue, to return to normal activities: a rapid review

   Spencer, L., Hendry, A., Makanjuola, A., Anthony, B., Davies, J., Pisavadia, K., Hughes, D., Fitzsimmons, D., Wilkinson, C., Edwards, R. T., Lewis, R., Cooper, A. & Edwards, A., 28 Jan 2023, 34 p. (MedRxiv).

   Research output: Working paper › Preprint

4. Published

   What is the long-term impact of COVID-19 on the Health-Related Quality of Life of individuals with mild symptoms (or non-hospitalised): A rapid review

   Spencer, L., Hendry, A., Makanjuola, A., Davies, J., Pisavadia, K., Hughes, D., Fitzsimmons, D., Wilkinson, C., Edwards, R. T., Lewis, R., Cooper, A. & Edwards, A., 9 Sept 2022, Health and Care Research Wales, 47 p.

   Research output: Working paper › Preprint

5. Review article › Research › Peer-reviewed
6. Published

   A Systematic Review of Economic Evaluations of Advanced Therapy Medicinal Products

   Lloyd Williams, H. & Hughes, D., Jun 2021, In: British Journal of Clinical Pharmacology. 87, 6, p. 2428-2443 16 p.

   Research output: Contribution to journal › Review article › peer-review

7. Published

   Evidence to support inclusion of pharmacogenetic biomarkers in randomised controlled trials

   Johnson, D., Jorgensen, A., Hughes, D. & Pirmohamed, M., 1 Sept 2019, In: Journal of Personalized Medicine. 9, 3, 19 p., 42.

   Research output: Contribution to journal › Review article › peer-review

8. Web publication/site › Research
9. Published

   Investigating factors influencing user choices to visit either general practitioners or community pharmacists in the management of minor ailments – piloting a discrete choice experiment

   Hughes, D., Hughes, D. A., Myles, S., Longo, M. & Lisles, C., 1 Mar 2008

   Research output: Non-textual form › Web publication/site

10. Other report › Research › Peer-reviewed
11. Published

    Have infection control and prevention measures resulted in any adverse outcomes for care home and domiciliary care residents and staff? Report number: RR_00018 (November 2021)

    Spencer, L., Hartfiel, N., Hendry, A., Anthony, B., Makanjuola, A., Bray, N., Hughes, D., Wilkinson, C., Fitzsimmons, D. & Edwards, R. T., 1 Nov 2021, 36 p.

    Research output: Book/Report › Other report › peer-review

12. Other report › Research › Not peer-reviewed
13. Published

    RES00019. Wales COVID-19 Evidence Centre. A rapid evidence summary indicating the evidence of the inverse care law in social care in Wales and has this been exacerbated by the COVID-19 pandemic?

    Spencer, L., Hendry, A., Makanjuola, A., Hughes, D., Wilkinson, C., Pisavadia, K., Davies, J., Fitzsimmons, D. & Edwards, R. T., Feb 2022, Welsh Government. 33 p.

    Research output: Book/Report › Other report

14. Published

    RES00038. Wales COVID-19 Evidence Centre. A rapid evidence summary of the cost impact of Long COVID on employment and caring responsibilities

    Spencer, L., Hendry, A., Davies, J., Pisavadia, K., Hughes, D. & Edwards, R. T., May 2022, Welsh Government. 18 p.

    Research output: Book/Report › Other report

15. Commissioned report › Research › Peer-reviewed
16. Published

    What innovations can address inequalities experienced by women and girls due to the COVID-19 pandemic across the different areas of life/domains: work, health, living standards, personal security, participation and education? Report number – RR00027 (January 2022). Gender Inequalities: COVID-19 initiatives

    Spencer, L., Hartfiel, N., Hendry, A., Anthony, B., Makanjuola, A., Pisavadia, K., Davies, J., Bray, N., Hughes, D., Wilkinson, C., Fitzsimmons, D. & Edwards, R. T., 15 Jan 2022, Health and Care Research Wales.

    Research output: Book/Report › Commissioned report › peer-review

17. Commissioned report › Research › Not peer-reviewed
18. Published

    A review of economic models for second-line chemotherapy in the management of advanced, metastatic breast cancer.

    Hughes, D. & Hughes, D. A., 1 Jan 2001, 2001 ed. Unknown.

    Research output: Book/Report › Commissioned report

19. Published

    AWMSG criteria for appraising new medicines.

    Hughes, D. & Hughes, D. A., 1 Jan 2007, 2007 ed. Unknown.

    Research output: Book/Report › Commissioned report

20. Published

    All Wales Medicines Strategy Group Final Appraisal Report - Abacavir 600mg/lamivudine 300mg (Kivexa) in antiretroviral combination therapy for the treatment of Human Immunodeficiency Virus infection in adults and adolescents from 12 years of age.

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Jan 2008, 2008 ed. Unknown.

    Research output: Book/Report › Commissioned report

21. Published

    All Wales Medicines Strategy Group Final Appraisal Report - Alemtuzumab (MabCampath) for the treatment of patients with B-cell chronic lymphocytic leukaemia for whom fludarabine combination chemotherapy is not appropriate.

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Jan 2008, 2008 ed. Unknown.

    Research output: Book/Report › Commissioned report

22. Published

    All Wales Medicines Strategy Group Final Appraisal Report - Ambrisentan (Volibris) for pulmonary arterial hypertension.

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Jan 2009, 2009 ed. Unknown.

    Research output: Book/Report › Commissioned report

23. Published

    All Wales Medicines Strategy Group Final Appraisal Report - Anidulafungin (Ecalta) for the treatment of invasive candidiasis in adult non-neutropenic patients.

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Jan 2009, 2009 ed. Unknown.

    Research output: Book/Report › Commissioned report

24. Published

    All Wales Medicines Strategy Group Final Appraisal Report - Atazanavir (Reyataz) in treatment-experienced patients.

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Jan 2008, 2008 ed. Unknown.

    Research output: Book/Report › Commissioned report

25. Published

    All Wales Medicines Strategy Group Final Appraisal Report - Atazanavir (Reyataz) in treatment-naïve patients.

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Jan 2008, 2008 ed. Unknown.

    Research output: Book/Report › Commissioned report

26. Published

    All Wales Medicines Strategy Group Final Appraisal Report - Buprenorphine/naloxone (Suboxone) as substitution treatment for opioid dependence.

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Jan 2008, 2008 ed. Unknown.

    Research output: Book/Report › Commissioned report

27. Published

    All Wales Medicines Strategy Group Final Appraisal Report - Deferasirox (Exjade) for the treatment of chronic iron overload due to blood transfusions.

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Jan 2008, 2008 ed. Unknown.

    Research output: Book/Report › Commissioned report

28. Published

    All Wales Medicines Strategy Group Final Appraisal Report - Docetaxel (Taxotere) for locally advanced squamous cell carcinoma of the head and neck.

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Jan 2008, 2008 ed. Unknown.

    Research output: Book/Report › Commissioned report

29. Published

    All Wales Medicines Strategy Group Final Appraisal Report - Emtricitabine/tenofovir DF (Truvada)

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Jan 2007, 2007 ed. Unknown.

    Research output: Book/Report › Commissioned report

30. Published

    All Wales Medicines Strategy Group Final Appraisal Report - Epoetin delta (Dynepo)

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Jan 2008, 2008 ed. Unknown.

    Research output: Book/Report › Commissioned report

31. Published

    All Wales Medicines Strategy Group Final Appraisal Report - Fondaparinux Sodium (Arixtra®) for STEMI.

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Jan 2008, 2008 ed. Unknown.

    Research output: Book/Report › Commissioned report

32. Published

    All Wales Medicines Strategy Group Final Appraisal Report - Fondaparinux Sodium (Arixtra®) for UA/NSTEMI.

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Jan 2008, 2008 ed. Unknown.

    Research output: Book/Report › Commissioned report

33. Published

    All Wales Medicines Strategy Group Final Appraisal Report - Icatibant (Firazyr) for symptomatic treatment of acute attacks of hereditary angioedema (HAE) in adults (with C1-esterase-inhibitor deficiency).

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Jan 2008, 2008 ed. Unknown.

    Research output: Book/Report › Commissioned report

34. Published

    All Wales Medicines Strategy Group Final Appraisal Report - Lenalidomide (Revlimid) for multiple myeloma.

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Jan 2008, 2008 ed. Unknown.

    Research output: Book/Report › Commissioned report

35. Published

    All Wales Medicines Strategy Group Final Appraisal Report - Maraviroc (Celsentri) for treatment-experienced adults infected only with CCR5-tropic HIV-1.

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Jan 2009, 2009 ed. Unknown.

    Research output: Book/Report › Commissioned report

36. Published

    All Wales Medicines Strategy Group Final Appraisal Report - Pegfilgrastim (Neulasta) for the reduction in the duration of neutropenia and the incidence of febrile neutropenia in patients treated with cytotoxic chemotherapy for malignancy.

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Jan 2008, 2008 ed. Unknown.

    Research output: Book/Report › Commissioned report

37. Published

    All Wales Medicines Strategy Group Final Appraisal Report - Raltegravir (Isentress) in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus (HIV-1) infection in treatment-experienced adult patients with evidence of HIV-1 replication despite ongoing antiretroviral therapy.

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Jan 2008, 2008 ed. Unknown.

    Research output: Book/Report › Commissioned report

38. Published

    All Wales Medicines Strategy Group Final Appraisal Report - Rufinamide (Inovelon) for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS).

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Jan 2008, 2008 ed. Unknown.

    Research output: Book/Report › Commissioned report

39. Published

    All Wales Medicines Strategy Group Final Appraisal Report - Stiripentol (Diacomit) for use in conjunction with clobazam and valproate in patients with severe myoclonic epilepsy in infancy.

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Jan 2008, 2008 ed. Unknown.

    Research output: Book/Report › Commissioned report

40. Published

    All Wales Medicines Strategy Group Final Appraisal Report - Tacrolimus (Advagraf) for the prophylaxis of transplant rejection in adult kidney or liver allograft recipients and the treatment of allograft rejection resistant to treatment with other immunosuppressive medicinal products in adult patients.

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Jan 2009, 2009 ed. Unknown.

    Research output: Book/Report › Commissioned report

41. Published

    All Wales Medicines Strategy Group Final Appraisal Report - Tenofovir disoproxil fumarate (Viread) for the treatment of hepatitis B.

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Jan 2008, 2008 ed. Unknown.

    Research output: Book/Report › Commissioned report

42. Published

    All Wales Medicines Strategy Group Final Appraisal Report - Teriparatide (Forsteo) for the treatment of osteoporosis in men at increased risk of fracture.

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Jan 2008, 2008 ed. Unknown.

    Research output: Book/Report › Commissioned report

43. Published

    All Wales Medicines Strategy Group Final Appraisal Report - Topotecan (Hycamtin®) for Small Cell Lung Carcinoma.

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Jan 2008, 2008 ed. Unknown.

    Research output: Book/Report › Commissioned report

44. Published

    All Wales Medicines Strategy Group Final Appraisal Report - Trabectedin (Yondelis) for advanced soft tissue sarcoma.

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Jan 2008, 2008 ed. Unknown.

    Research output: Book/Report › Commissioned report

45. Published

    All Wales Medicines Strategy Group Final Appraisal Report - Ziconotide (Prialt) for the intrathecal treatment of severe, chronic pain.

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Jan 2008, 2008 ed. Unknown.

    Research output: Book/Report › Commissioned report

46. Published

    All Wales Medicines Strategy Group Final Appraisal Report – Clofarabine (Evoltra)

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Jan 2007, 2007 ed. Unknown.

    Research output: Book/Report › Commissioned report

47. Published

    All Wales Medicines Strategy Group Final Appraisal Report – Co-careldopa intestinal gel (Duodopa).

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Jan 2007, 2007 ed. Unknown.

    Research output: Book/Report › Commissioned report

48. Published

    All Wales Medicines Strategy Group Final Appraisal Report – Darunavir (Prezista)

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Jan 2007, 2007 ed. Unknown.

    Research output: Book/Report › Commissioned report

49. Published

    All Wales Medicines Strategy Group Final Appraisal Report – Dasatinib (Sprycel®) Chronic, accelerated or blast phase CML.

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Jan 2007, 2007 ed. Unknown.

    Research output: Book/Report › Commissioned report

50. Published

    All Wales Medicines Strategy Group Final Appraisal Report – Dasatinib (Sprycel®) Lymphoid blast CML and PH+ ALL.

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Jan 2007, 2007 ed. Unknown.

    Research output: Book/Report › Commissioned report

51. Published

    All Wales Medicines Strategy Group Final Appraisal Report – Dexrazoxane (Savene)

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Jan 2007, 2007 ed. Unknown.

    Research output: Book/Report › Commissioned report

52. Published

    All Wales Medicines Strategy Group Final Appraisal Report – Emtricitabine (Emtriva)

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Jan 2007, 2007 ed. Unknown.

    Research output: Book/Report › Commissioned report

53. Published

    All Wales Medicines Strategy Group Final Appraisal Report – Idursulfase (Elaprase)

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Jan 2007, 2007 ed. Unknown.

    Research output: Book/Report › Commissioned report

54. Published

    All Wales Medicines Strategy Group Final Appraisal Report – Parathyroid hormone (Preotact)

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Jan 2007, 2007 ed. Unknown.

    Research output: Book/Report › Commissioned report

55. Published

    All Wales Medicines Strategy Group Final Appraisal Report – Tipranavir (Aptivus).

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Jan 2007, 2007 ed. Unknown.

    Research output: Book/Report › Commissioned report

56. Published

    All Wales Medicines Strategy Group Final Assessment Report – Agalsidase alfa (Replagal)

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Jan 2007, 2007 ed. Unknown.

    Research output: Book/Report › Commissioned report

57. Published

    Development of an economic model to evaluate the cost-effectiveness of rival therapies for treating Crohn’s disease.

    Hughes, D., Kikuchi, T., Bodger, K. & Hughes, D. A., 1 Jan 2008, 2008 ed. Unknown.

    Research output: Book/Report › Commissioned report